Abemaciclib Combo Therapy Improves Outcome in Certain Advanced Breast Cancer Patients

Abemaciclib Combo Therapy Improves Outcome in Certain Advanced Breast Cancer Patients
Adding abemaciclib to endocrine therapy can reduce the risk of breast cancer progressing in newly diagnosed postmenopausal women, according to interim results of a Phase 3 clinical trial. Italian researcher Angelo Di Leo presented the findings at the European Society for Medical Oncology Congress in Madrid, Sept. 8-12. The MONARCH 3 study (NCT02246621) involves hormone receptor (HR)-positive, HER2-negative advanced breast cancer. Dr.

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *